Harrow launches partnership with PhilRx to expand access to VEVYE
VEVYE Access for All aims to reduce barriers to dry eye disease therapy via a partnership with PhilRx.
(Image credit: Adobe Stock / ©New Africa)
Harrow has announced a new initiative, VEVYE Access for All, in hopes of removing obstacles to dry eye therapy via a partnership with PhilRx, a national mail-order pharmacy partner, which will help expedite prescription fulfillment with no prior authorization and flat-rate refill program. This program is in place for prescriptions of cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow) and promises a $59 price tag per bottle, effective immediately. Patients whose prescriptions are covered by commercial insurance may pay as little as $0 through this program.
By partnering with a mail-order pharmacy, Harrow plans to provide quick dispensing of cyclosporine 0.1%. Providers can participate by sending prescriptions to PhilRx via electronic medical record (EMR), and discounted pricing and benefits will be automatically applied at the pharmacy if the patient is eligible. Harrow plans to expand this program through all pharmacy networks over time.
“With VEVYE Access for All, we are disrupting the status quo in U.S. prescription dry eye access,” Mark L. Baum, Chief Executive Officer of Harrow, said in a press release. “For too long, patients, doctors, and pharmaceutical companies have been at the mercy of unseen middlemen who act as access gatekeepers, using needless red tape to prevent patients from benefitting from medications they are prescribed. These tactics are a horribly unfair financial and logistical burden on eyecare professionals, and patients are often left to pay higher out‑of‑pocket co-payments for drugs that may not even be what their doctor prescribed. This program puts power back where it belongs – in the hands of eye care professionals and their patients – by simplifying the prescribing and dispensing process and removing access impediments for all patients, creating a more frictionless path to therapy. We believe every patient who can benefit from VEVYE should have access – quickly and affordably, and Harrow is proud to lead the way and drive this needed change.”
The VEVYE Access for All program boasts a few key benefits, including:
- No prior authorization submissions for eligible patients: Eye care providers are not required to submit prior authorization paperwork, step edits, and other documentation before prescribing cyclosporine 0.1% through this program.
- Quick prescription processing: Through the partnership with PhilRx, prescriptions can be filled and delivered to a patient’s home for free.
- Discounted patient costs: Patients who use commercial insurance may pay as little as $0 for their first prescription of cyclosporine 0.1% ophthalmic solution. Refills are $59 for eligible patients, and 3-bottle orders offer additional discounts.
- Money-back guarantee: A no-questions-asked money-back guarantee is available to patients who pay cash and do not have commercial or government insurance (including, but not limited to, Medicare or Medicaid). The guarantee is only available for one fill.
Paul M. Karpecki, OD, Director of Cornea and External Disease at the Kentucky Eye Institute, added, “After decades of working with dry eye and ocular surface disease patients, I have seen firsthand the challenges patients face in accessing effective prescription dry eye treatments. I am so pleased that Harrow is addressing the giant elephant in the room – insurance company tactics that often prevent or delay critical care. VEVYE Access for All is a game‑changer, eliminating these barriers, cutting out‑of‑pocket expenses, and empowering physicians to focus on delivering the best possible care. My staff is so excited about this program, too! Many of my dry eye patients are already experiencing the clinical benefits of VEVYE, and this new program will enable us to extend these benefits to all dry eye sufferers, regardless of their insurance status.”
To learn more about the VEVYE Access for All program, including full terms and conditions for eligibility, visit the VEVYE website.
